Novo Nordisk targets over five blockbuster drugs by 2030
CEO Mike Doustdar said at Novo Nordisk’s Capital Markets Day in London the company aims to launch more than five blockbuster drugs by 2030 and deliver more than 150 billion Danish crowns in pipeline sales in 2035.
Novo Nordisk aims to launch more than five blockbuster drugs by 2030 and to deliver more than 150 billion Danish crowns ($23 billion) in pipeline sales in 2035, CEO Mike Doustdar said at the company’s Capital Markets Day in London.